ERBB4 and non-small cell lung carcinoma: Figure 9A shows the effects of inhibition of HER4 by the TK inhibitor, ibrutinib, or by the GRPR receptor antagonist, PD176252, on NCI-H522 and NCI-H66 NSCLC proliferation.